found that MRX‐2843, an MerTK inhibitor, could decrease immunosuppressive M2‐like glioblastoma‐associated macrophages and microglia (GAMs).[230] Therefore, development of nanotechnology for targeting inhibition of MerTK on macrophages is necessary for further improving MerTK‐dependent anti‐tumor therapy. The gene discussed is MERTK; the disease is glioblastoma.